Nutraceuticals and nutritional supplements for the treatment of bipolar disorder : protocol for a systematic review

Melanie M. Ashton; Michael Berk; Chee H. Ng; Malcolm Hopwood; Bianca Kavanagh; Lana J. Williams; Jerome Sarris; Olivia M. Dean

doi:10.1136/bmjopen-2018-025640

Nutraceuticals and nutritional supplements for the treatment of bipolar disorder : protocol for a systematic review

Melanie M. Ashton, Michael Berk, Chee H. Ng, Malcolm Hopwood, Bianca Kavanagh, Lana J. Williams, Jerome Sarris, Olivia M. Dean

Western Sydney University

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Introduction First line pharmacological treatments for bipolar disorder (BD) can leave shortfalls in recovery leading to patients seeking alternative and adjunctive treatments such as nutraceuticals. This protocol for a systematic review and proposed meta-analysis aims to answer the research question: in patients with BD, how does use of nutraceutical treatments compare with placebo in reducing depressive and mania symptoms? Methods and analysis Clinical trials will be identified through database searches using PubMed via PubMed, EMBASE via embase.com, Cochrane Central Register of Controlled Clinical Trials (CENTRAL) via cochranelibrary.com and CINAHL Complete via EBSCO. Search terms for BD and specific nutraceuticals (75 total search terms) will be used. Double-blind, randomised, controlled, clinical trials of adults with BD will be included in the review. Risk of bias will be assessed using the Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Ethics and dissemination This review will only look at published data (already reviewed for ethical compliance); therefore, ethical approval is not required. We aim to publish the systematic review in a peer-reviewed journal and present at conferences. PROSPERO registration number CRD42019100745.

Original language	English
Article number	e025640
Number of pages	5
Journal	BMJ Open
Volume	9
Issue number	4
DOIs	https://doi.org/10.1136/bmjopen-2018-025640
Publication status	Published - 2019

Open Access - Access Right Statement

©Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Keywords

dietary supplements
functional foods
manic-depressive illness
medical protocols
therapeutic use

Access to Document

10.1136/bmjopen-2018-025640

Cite this

@article{2ccf7ec8e04944c9be6e091c19008958,

title = "Nutraceuticals and nutritional supplements for the treatment of bipolar disorder : protocol for a systematic review",

abstract = "Introduction First line pharmacological treatments for bipolar disorder (BD) can leave shortfalls in recovery leading to patients seeking alternative and adjunctive treatments such as nutraceuticals. This protocol for a systematic review and proposed meta-analysis aims to answer the research question: in patients with BD, how does use of nutraceutical treatments compare with placebo in reducing depressive and mania symptoms? Methods and analysis Clinical trials will be identified through database searches using PubMed via PubMed, EMBASE via embase.com, Cochrane Central Register of Controlled Clinical Trials (CENTRAL) via cochranelibrary.com and CINAHL Complete via EBSCO. Search terms for BD and specific nutraceuticals (75 total search terms) will be used. Double-blind, randomised, controlled, clinical trials of adults with BD will be included in the review. Risk of bias will be assessed using the Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Ethics and dissemination This review will only look at published data (already reviewed for ethical compliance); therefore, ethical approval is not required. We aim to publish the systematic review in a peer-reviewed journal and present at conferences. PROSPERO registration number CRD42019100745.",

keywords = "dietary supplements, functional foods, manic-depressive illness, medical protocols, therapeutic use",

author = "Ashton, {Melanie M.} and Michael Berk and Ng, {Chee H.} and Malcolm Hopwood and Bianca Kavanagh and Williams, {Lana J.} and Jerome Sarris and Dean, {Olivia M.}",

year = "2019",

doi = "10.1136/bmjopen-2018-025640",

language = "English",

volume = "9",

journal = "BMJ Open",

issn = "2044-6055",

publisher = "BMJ Group",

number = "4",

}

TY - JOUR

T1 - Nutraceuticals and nutritional supplements for the treatment of bipolar disorder : protocol for a systematic review

AU - Ashton, Melanie M.

AU - Berk, Michael

AU - Ng, Chee H.

AU - Hopwood, Malcolm

AU - Kavanagh, Bianca

AU - Williams, Lana J.

AU - Sarris, Jerome

AU - Dean, Olivia M.

PY - 2019

Y1 - 2019

N2 - Introduction First line pharmacological treatments for bipolar disorder (BD) can leave shortfalls in recovery leading to patients seeking alternative and adjunctive treatments such as nutraceuticals. This protocol for a systematic review and proposed meta-analysis aims to answer the research question: in patients with BD, how does use of nutraceutical treatments compare with placebo in reducing depressive and mania symptoms? Methods and analysis Clinical trials will be identified through database searches using PubMed via PubMed, EMBASE via embase.com, Cochrane Central Register of Controlled Clinical Trials (CENTRAL) via cochranelibrary.com and CINAHL Complete via EBSCO. Search terms for BD and specific nutraceuticals (75 total search terms) will be used. Double-blind, randomised, controlled, clinical trials of adults with BD will be included in the review. Risk of bias will be assessed using the Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Ethics and dissemination This review will only look at published data (already reviewed for ethical compliance); therefore, ethical approval is not required. We aim to publish the systematic review in a peer-reviewed journal and present at conferences. PROSPERO registration number CRD42019100745.

AB - Introduction First line pharmacological treatments for bipolar disorder (BD) can leave shortfalls in recovery leading to patients seeking alternative and adjunctive treatments such as nutraceuticals. This protocol for a systematic review and proposed meta-analysis aims to answer the research question: in patients with BD, how does use of nutraceutical treatments compare with placebo in reducing depressive and mania symptoms? Methods and analysis Clinical trials will be identified through database searches using PubMed via PubMed, EMBASE via embase.com, Cochrane Central Register of Controlled Clinical Trials (CENTRAL) via cochranelibrary.com and CINAHL Complete via EBSCO. Search terms for BD and specific nutraceuticals (75 total search terms) will be used. Double-blind, randomised, controlled, clinical trials of adults with BD will be included in the review. Risk of bias will be assessed using the Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Ethics and dissemination This review will only look at published data (already reviewed for ethical compliance); therefore, ethical approval is not required. We aim to publish the systematic review in a peer-reviewed journal and present at conferences. PROSPERO registration number CRD42019100745.

KW - dietary supplements

KW - functional foods

KW - manic-depressive illness

KW - medical protocols

KW - therapeutic use

UR - http://handle.westernsydney.edu.au:8081/1959.7/uws:51457

U2 - 10.1136/bmjopen-2018-025640

DO - 10.1136/bmjopen-2018-025640

M3 - Article

SN - 2044-6055

VL - 9

JO - BMJ Open

JF - BMJ Open

IS - 4

M1 - e025640

ER -

Nutraceuticals and nutritional supplements for the treatment of bipolar disorder : protocol for a systematic review

Abstract

Open Access - Access Right Statement

Keywords

Access to Document

Other files and links

Fingerprint

Cite this